PRS
SUPN icon

Pinkerton Retirement Specialists’s Supernus Pharmaceuticals SUPN Stock Holding History

Pinkerton Retirement Specialists’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-905
Closed -$23K – 442
2016
Q4 		$23K Sell
905
-10
-1% -$223 0.01% 296
2016
Q3 		$23K Buy
915
+5
+0.5% +$113 0.01% 296
2016
Q2 		$19K Buy
+910
New +$16.1K 0.01% 309

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Pinkerton Retirement Specialists's SUPN Position: Q1 2017 in Review

Pinkerton Retirement Specialists sold out of Supernus Pharmaceuticals (SUPN) in Q1 2017, closing a stake of 905 shares — an estimated $23K sold.

Pinkerton Retirement Specialists first reported a position in SUPN in Q2 2016 and held it in 3 quarters. The position peaked at $23K in Q4 2016. 246 funds tracked by Wall St. Rank hold SUPN as of Q1 2017.

  • Pinkerton Retirement Specialists reported no remaining Supernus Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Pinkerton Retirement Specialists sold 905 Supernus Pharmaceuticals shares in Q1 2017, an estimated $23K.
  • Pinkerton Retirement Specialists first reported a position in Supernus Pharmaceuticals in Q2 2016 and held it in 3 quarters.
  • Pinkerton Retirement Specialists's Supernus Pharmaceuticals position peaked at $23K in Q4 2016.
  • 246 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2017.

Based on Pinkerton Retirement Specialists's 13F filing for Q1 2017, filed 15 May 2017.